# US 2012/0251455 A1 · Hair Growth-Inhibiting Agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251455 A1
- Document ID: US20120251455A1
- Status: Published application
- Kind: A1
- Application number: 13/360,419
- Filed: 2012-01-27
- Published: 2012-10-04
- Earliest claimed: 2007-02-19
- Assignees: National Institute of Advanced Industrial Science and Technology
- Inventors: Toru IMAMURA; Miho KIMURA; Mitsuko KAWANO; Nozomi TSUJINO; Akiko KURAMOCHI; Yuko ODA; Kaori MOTOMURA; Masashi SUZUKI; Masahiro ASADA; Azusa KAMEYAMA; Sumie TOGAYACHI; Syuichi OKA
- Web page: https://patentgrep.com/patent/US20120251455A1

## CPC

- C07K 14/43536: {from worms}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61Q 7/02: Preparations for inhibiting or slowing hair growth
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 2333/50: Fibroblast growth factors [FGF]
- G01N 2500/10: involving cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7 (depends on 17)

A method of screening according to claim 17, said screening comprising the following steps (a) to (c):
(a) compulsively expressing at least one FGF receptor gene selected from FGFR1c, FGFR2c, FGFR3c and FGFR4 on the surface of a cell by means of genetic engineering and culturing the cell;
(b) bringing a test substance into contact with the cell system obtained in step (a) having the FGF receptor on cell surfaces; and
(c) selecting those test substances which exhibited FGF18 like cell growth promoting activity in step (b).

### Claim 8 (depends on 17)

A method of screening according to claim 17, said method screening comprising the following steps (a) to (c):
(a) compulsively expressing four FGF receptor genes, FGFR1c, FGFR2c, FGFR3c and FGFR4, on respective cell surfaces by means of genetic engineering and culturing the four cells;
(b) bringing a test substance into contact with the four cell systems obtained in step (a) having the FGF receptors on cell surfaces; and
(c) selecting those test substances which, similar to EGF18, exhibit markedly higher cell growth promoting activity on the FGFR3c-expressing cell and the FGFR4-expressing cell than on the FGFR1c-expressing cell and the FGFR2c-expressing cell at the same concentration.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the cell on whose surface the FGF receptor is compulsively expressed is mouse IL-3-dependent Ba/F3 cell strain.

### Claim 10 (depends on 17)

A method of screening according to claim 17, said screening comprising the following steps (a) to (c):
(a) compulsively expressing at least one FGF receptor gene selected from FGFR1c, FGFR2c, FGFR3c and FGFR4 on the surface of a cell by means of genetic engineering and culturing the cell;
(b) bringing, together with FGF18, a test substance into contact with the cell system obtained in step (a) having the FGF receptor on cell surfaces; and
(c) selecting those cell systems which exhibited a higher cell growth promoting activity in step (b) than when FGF18 was allowed to act singly.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the FGF receptor is FGFR3c.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the FGF receptor is FGFR4.

### Claim 13 (depends on 10)

The method according claim 10, wherein the cell on whose surface the FGF receptor is compulsively expressed is mouse IL-3-dependent Ba/F3 cell strain.

### Claim 14 (depends on 17)

A method of screening according to claim 17, said screening comprising the following steps (a) to (d):
(a) preparing an experimental animal or a cultured animal cell capable of expressing FGF18 to an observable extent;
(b) bringing a test substance into contact with or administering the same to the experimental animal, or bringing the same into contact with the cultured animal cell;
(c) monitoring the expression of FGF18 in the experimental animal or the cultured animal cell after step (b); and
(d) selecting those test substances which have a function of promoting the expression of FGF18.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the expression of FGF18 is monitored in step (c) by extracting mRNA from the experimental animal or the cultured animal cell after step (b) and then analyzing the mRNA level of expressed FGF18; and those test substances which have a function of promoting the expression of FGF18 are selected in step (d) by selecting systems that exhibited higher levels of FGF18 mRNA than when FGF18 was not allowed to act.

### Claim 16 (depends on 8)

The method according to claim 8, wherein the cell on whose surface the FGF receptor is compulsively expressed is mouse IL-3-dependent Ba/F3 cell strain.

### Claim 17

A method of screening from test substances, comprising:
screening for a substance that promotes the activity or expression of FGF18 or an FGF18-like active substance as a candidate for a hair growth-inhibiting agent or a hair removing agent.
